New biomarkers exploration and nomogram construction of prognostic and immune-related adverse events of advanced non-small cell lung cancer patients receiving immune checkpoint inhibitors

BACKGROUND: Immune checkpoint inhibitors (ICIs) are regarded as the most promising treatment for advanced-stage non-small cell lung cancer (aNSCLC). Unfortunately, there has been no unified accuracy biomarkers and systematic model specifically identified for prognostic and severe immune-related adve...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Xuwen, Chen, Xi, Long, Xiang, Zeng, Chao, Zhang, Zhihan, Fang, Weiyi, Xu, Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9972722/
https://www.ncbi.nlm.nih.gov/pubmed/36849947
http://dx.doi.org/10.1186/s12931-023-02370-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9972722/
https://www.ncbi.nlm.nih.gov/pubmed/36849947
http://dx.doi.org/10.1186/s12931-023-02370-0

Ejemplares similares